Medtech Insight is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By


igeneon AG

Division of Aphton Corp.

Latest From igeneon AG

Serono Deals Its Way Into Oncology

It ought to be hard to convince an oncology-focused biotech to license its crown jewel to a firm without experience developing oncology drugs, but Serono SA was able to do just that-twice in the span of eight days-when it in-licensed Phase II and Phase III oncology programs, respectively, from Micromet AG and CancerVax Corp. in December.
BioPharmaceutical Strategy

immatics biotechnologies GMBH

immatics biotechnologies GMBH aims to identify tumor-associated peptides by directly measuring their presence in cancer tissue and then creating cancer vaccines from combinations of the most prevalent peptides associated with a particular tumor. The Tuebingen-based firm's proprietary platform combines genomics, mass spectrometry and cell-based assay systems to offer better speed and precision than existing technologies.
BioPharmaceutical Europe

Micromet: Coping with the Fallout When a Partner is Acquired

When Micromet's development partner for lead anti-carcinoma antibody MT201 was bought by Cell Therapeutics in mid-2003, the German biotech was forced to restructure significantly in order to continue funding the program through Phase II trials alone. Micromet isn't the only biotech to see a partnering deal scuppered by M&A. But it and others have shown that these days, a rejected program doesn't mean a dead program. Micromet has since signed a manufacturing partner and its plans to take the program through Phase II alone remain on track.
BioPharmaceutical Europe

Glycart Biotechnology AG

Glycart Biotechnology is a Zurich-based start-up that aims to generate antibodies with improved glycosylation characteristics to increase therapeutic potency. The firm's GlycoMAb technology can be applied to customers own cellular production systems to generate more effective versions of existing or experimental antibody therapeutics.
BioPharmaceutical Europe
See All

Company Information

  • Industry
  • Biotechnology
    • Large Molecule
      • Antibodies
  • Pharmaceuticals
    • Vaccines
  • Therapeutic Areas
  • Cancer
  • Dermatology
  • Alias(es)
  • Ownership
  • Private
  • Headquarters
  • Worldwide
    • Europe
      • Western Europe
        • Austria
  • Parent & Subsidiaries
  • Aphton Corp.
  • Senior Management
  • Hans Loibner, PhD, CEO
    Eugen Stermetz, CFO
    Gottfried Himmler, PhD, CSO
  • Contact Info
  • igeneon AG
    Phone: (43) 190 250
    Brunner Str. 69, Obj. 3
    Vienna, 1230